Abstract:Macrocyclic peptides are predominantly peptide structures bearing one or more rings and spanning multiple amino acid residues. Macrocyclization has become a common approach for improving the pharmacological properties and bioactivity of peptides. A variety of ribosomal-derived and non-ribosomal synthesized cyclization approaches have been established. The biosynthesis of backbone macrocyclic peptides using seven new emerging methodologies will be discussed with regard to the features and strengths of each platform rather than medicinal chemistry tools. The mRNA display variant, known as the random nonstandard peptide integrated discovery (RaPID) platform, utilizes flexible in vitro translation (FIT) to access macrocyclic peptides containing nonproteinogenic amino acids (NAAs). As a new discovery approach, the ribosomally synthesized and post-translationally modified peptides (RiPPs) method involves the combination of ribosomal synthesis and the phage screening platform together with macrocyclization chemistries to generate libraries of macrocyclic peptides. Meanwhile, the split-intein circular ligation of peptides and proteins (SICLOPPS) approach relies on the in vivo production of macrocyclic peptides. In vitro and in vivo peptide library screening is discussed as an advanced strategy for cyclic peptide selection. Specifically, biosynthetic bicyclic peptides are highlighted as versatile and attractive modalities. Bicyclic peptides represent another type of promising therapeutics that allow for building blocks with a heterotrimeric conjugate to address intractable challenges and enable multimer complexes via linkers. Additionally, we discuss the cell-free chemoenzymatic synthesis of macrocyclic peptides with a non-ribosomal catalase known as the non-ribosomal synthetase (NRPS) and chemo-enzymatic approach, with recombinant thioesterase (TE) domains. Novel insights into the use of peptide library tools, activity-based two-hybrid screening, structure diversification, inclusion of NAAs, combinatorial libraries, expanding the toolbox for macrocyclic peptides, bicyclic peptides, chemoenzymatic strategies, and future perspectives are presented. This review highlights the broad spectrum of strategy classes, novel platforms, structure diversity, chemical space, and functionalities of macrocyclic peptides enabled by emerging biosynthetic platforms to achieve bioactivity and for therapeutic purposes.

Coiled Coil Peptide Tiles (CCPTs): Expanding the Peptide Building Block Design with Multivalent Peptide Macrocycles

Coiled Coil Peptide Tiles (CCPTs): Multivalent Peptide Macrocycles for Expanding the Coiled Coil Assembly Toolkit

Self-assembly of cyclic dipeptides: platforms for functional materials.

Peptide/protein-based Macrocycles: from Biological Synthesis to Biomedical Applications

Recent Advances in Peptide Macrocyclization Strategies.

Ultra-confined controllable cyclic peptides as supramolecular biomaterials

Current Synthetic Approaches to Peptide and Peptidomimetic Cyclization

Macrocyclic Peptide Construction Through C-H Activation Strategy.

Advancing multicomponent strategies to macrobicyclic peptides

Bioorthogonal Polymerization of Coiled-Coil Peptides

Recent Developments in Peptide Macrocyclization

Biosynthetic Strategies for Macrocyclic Peptides

Cyclotides, a Novel Ultrastable Polypeptide Scaffold for Drug Discovery

MOrPH-PhD: An Integrated Phage Display Platform for the Discovery of Functional Genetically Encoded Peptide Macrocycles

Isothiocyanate Enabled Versatile Cyclizations of Phage Dis-played Peptides for the Discovery of Macrocyclic Binders

Linearizable Macrocyclic Peptide Libraries for Affinity Selection-Mass Spectrometry

Cyclic arylopeptoid oligomers: synthesis and conformational propensities of peptide-mimetic aromatic macrocycles

Triscysteine disulfide-directing motifs enabling design and discovery of multicyclic peptide binders

Applications of Cyclic Peptide Nanotubes

Preorganized cyclic modules facilitate the self-assembly of protein nanostructures

Display Technologies for Expanding the Pharmaceutical Applications of Cyclotides